Privi Speciality Chemicals saw a 35% jump in net profit for Q1 FY27. The company reported increased revenue and improved margins, alongside plans for significant capacity expansion and a group merger.
Privi Speciality Chemicals Q1 FY27 Results Show Strong Profit Growth
Privi Speciality Chemicals Ltd. reported a consolidated profit after tax (PAT) of ₹83.2 crore for the first quarter of FY27, marking a significant 35% increase from ₹61.46 crore in the same quarter last year. ## What just happened The company's total income for Q1 FY27 stood at ₹681.42 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) were ₹167.47 crore, with EBITDA margins maintained at a healthy 24.58%. ## Why this matters The strong PAT growth, driven by a 20.01% year-on-year increase in consolidated revenue, indicates improved profitability. This revenue growth was attributed to volume increases, price adjustments, and a favourable product mix. The reduction in the working capital cycle to 108 days from 141 days also points to enhanced operational efficiency. ## The backstory Privi Speciality Chemicals has been focused on expanding its capacities and streamlining its group structure. The company has outlined a substantial capital expenditure plan to support its growth ambitions. ## What changes now Phase-1 of the capacity expansion, set to increase capacity from 48,000 MT to 54,000 MT, is expected to be commercialized by mid-August 2026. Phase-2 completion by September 2027 will further boost capacity to 66,000 MT. A total capex of ₹850-900 crore is planned over the next three years. Additionally, a merger scheme involving Privi Speciality Chemicals, Privi Fine Sciences, and Privi Biotechnologies has been filed with the NCLT to simplify the group's structure and achieve operational synergies. ## Risks to watch Execution risks related to the timely completion of capacity expansions and the NCLT merger process are key factors for investors to monitor. ## Peer comparison (No peer comparison data available in the filing) ## Context metrics (time-bound) Consolidated PAT for Q1 FY27: ₹83.2 crore (up 35% YoY). Consolidated revenue for Q1 FY27: ₹681.42 crore. Working capital cycle reduced to 108 days from 141 days. ## What to track next Investors will be closely watching the progress of the Phase-1 and Phase-2 capacity expansions and the successful completion of the NCLT merger. The company's long-term targets of ₹5,000 crore revenue and ₹1,000 crore EBITDA remain key benchmarks.
